Lab21 Announces Appointment of Industry Expert Fraser Logue
News Feb 21, 2012
Lab21 Limited has announced the appointment of Fraser Logue as Group Director of Quality, Regulatory Affairs & Operations Excellence based in the UK.
Dr Logue served two decades in divisions of Abbott Laboratories, most recently as Division Vice President World Wide Manufacturing for Abbott Diabetes Care, moving from Division Vice President European Operations.
He previously served as Operations Director for Abbott Diagnostics Division Ireland, Director of Quality & Regulatory and Marketing Manager for Abbott Diagnostics Division in Germany.
Graham Mullis, CEO of Lab21, said: “I am delighted to have someone of Fraser’s experience join Lab21, especially at a time when we expect to see significant organic growth during the next few years. His senior level international management experience and operations capabilities will ensure Lab21 will meet the demands of increasing sales, entering new markets including the US and the launch of new products.”
Dr Logue said: “Lab21 has achieved remarkable progress within the past 4 years, growing five times in size. I am looking forward to working with and contributing to the future success of Lab21.”
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.